Client News

Posted: October 31, 2014, 10:04 pm
[AP] - A look at the 10 biggest percentage decliners on Nasdaq at the close of trading: Ohr Pharmaceutical fell 32.1 percent to $7.74. Web.com Inc. fell 19.9 percent to $27.70. Aemetis Inc. fell 12.5 percent ...
Posted: October 31, 2014, 10:04 pm
Posted: October 31, 2014, 10:04 pm
[Business Wire] - Ignyta, Inc. , an precision oncology biotechnology company, announced today that it will release its third quarter 2014 financial results after the market closes on Friday, November 7, 2014.
Posted: October 31, 2014, 9:29 pm
[PR Newswire] - IRVINE, Calif., Oct. 31, 2014 /PRNewswire/ -- AtheroNova Inc. (AHRO), a biotech company focused on the research and development of compounds to safely regress atherosclerotic plaque and improve lipid profiles in humans, today announced the closing of its follow-on public offering of 4,000,000 shares of common stock, with each share of common stock being sold together with 1.25 warrants to purchase one share of common stock. The securities were sold at a price to the public of $0.75 per share of common stock and $0.00001 per warrant. The gross proceeds from this offering to AtheroNova are approximately $3,000,050, before deducting underwriting discounts and commissions and estimated offering expenses payable by AtheroNova. AtheroNova has granted the underwriters a 45-day option to purchase up to an additional 600,000 shares of its common stock and/or warrants to purchase up to an aggregate of 750,000 shares of its common stock. Aegis Capital Corp. is acting as the sole book-running manager for the offering.
Posted: October 31, 2014, 8:13 pm
[Business Wire] - Levi & Korsinsky, LLP is investigating Alcobra Ltd. in connection with possible violations of federal securities laws by the Board
Posted: October 31, 2014, 3:53 pm
Posted: October 31, 2014, 1:10 pm
[at noodls] - WARRINGTON, Pa. , Oct. 30, 2014 /PRNewswire/ -- Discovery Laboratories, Inc. (NASDAQ: DSCO), a specialty biotechnology company dedicated to advancing a new standard in respiratory critical care, today ...
Posted: October 30, 2014, 9:51 pm
[PR Newswire] - WARRINGTON, Pa., Oct. 30, 2014 /PRNewswire/ -- Discovery Laboratories, Inc. (DSCO), a specialty biotechnology company dedicated to advancing a new standard in respiratory critical care, today announced organizational changes to the development leadership team and a special advisory appointment to augment the company's expertise in neonatology and aerosolized drug delivery. Steven G. Simonson, M.D., has been appointed Senior Vice President and Chief Development Officer, with responsibility for research, clinical development, aerosol device development, regulatory affairs, and patient safety / pharmacovigilance.
Posted: October 30, 2014, 8:51 pm
[at noodls] - WIXOM, Mich., Oct. 30, 2014 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (Nasdaq:RMTI), a fully integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) ...
Posted: October 30, 2014, 8:45 pm
[at noodls] - /releasedetail.cfm?ReleaseID=878714 Previous Release COPPELL, Texas, Oct. 30, 2014 (GLOBE NEWSWIRE) -- ZS Pharma (Nasdaq:ZSPH), a biopharmaceutical company developing novel treatments for kidney, cardiovascular, ...
Posted: October 30, 2014, 8:29 pm
[at noodls] - New York, Oct. 30, 2014 - NeoStem, Inc. (Nasdaq:NBS), a biopharmaceutical company developing novel cell based therapeutics designed to prevent, treat or cure disease, today announced financial results ...
Posted: October 30, 2014, 8:18 pm
[GlobeNewswire] - NEW YORK -- NeoStem, Inc. , a biopharmaceutical company developing novel cell based therapeutics designed to prevent, treat or cure disease, today announced financial results for the third quarter of 2014 ...
Posted: October 30, 2014, 8:14 pm
Posted: October 30, 2014, 8:07 pm
[GlobeNewswire] - WIXOM, Mich. -- Rockwell Medical, Inc. , a fully integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products and services for ...
Posted: October 30, 2014, 8:01 pm
[GlobeNewswire] - COPPELL, Texas -- ZS Pharma , a biopharmaceutical company developing novel treatments for kidney, cardiovascular, liver and metabolic disorders, today announced that data from ZS003, a pivotal Phase 3 ...
Posted: October 30, 2014, 8:00 pm